The Indiana Alzheimer Disease Center is solely committed to supporting the National Alzheimer’s Project Act (NAPA), an initiative to lead research to prevent and effectively treat Alzheimer disease by 2025. Signed by President Barack Obama, the Act offers a historic opportunity to address the many challenges facing people with Alzheimer’s and their families.
Pioneering Global Collaboration
Dianne Trauring and Nancy Carpenter lost their mother in 2010 after a long battle with Alzheimer’s disease. Stories like theirs drive Indiana University School of Medicine physicians and scientists to focus on ways to develop new ways to diagnose, treat and ultimately prevent Alzheimer’s disease.
There has never been a more critical or dynamic time for Alzheimer’s research. More than 35 million people worldwide have dementia, a number that is expected to nearly double every 20 years. In the United States alone, an estimated 5.5 million people are suffering from Alzheimer’s disease or related dementias.
IU School of Medicine’s multidisciplinary team of researchers understands that collaboration is key to make real progress. Experts from across the school work hand-in-hand with partners from throughout academia and industry with the goal of ending suffering from Alzheimer’s disease and related dementias.
National Leader in Alzheimer’s Research
Beyond conducting leading-edge research in its own laboratories, Indiana University School of Medicine physicians and scientists provide critical expertise to support research underway throughout the country. The federal government has designated IU School of Medicine as the national site that collects blood, DNA, tissue and other samples from tens of thousands of Americans with Alzheimer’s disease, providing a wealth of information for scientists to mine. The school is also developing laboratory models that are used by scientists throughout the country to study genetic contributors to the disease and test potential treatments. And IU School of Medicine is leading a nationwide study of a rare and particularly devastating early-onset form of Alzheimer’s that afflicts patients in the prime of their lives.
Recruiting Healthy and Affected Participants for Clinical Trials
Successful clinical trials rely on both healthy individuals and people with Alzheimer’s disease to identify symptoms and gene markers that indicate the disease. IU School of Medicine has many active clinical trials. Information on these studies, including who’s needed to help advance these research studies, is available.
Accomplished Faculty Investigators
Advanced technology driving patient-centered research
Indiana University School of Medicine is training the next generation of researchers specifically focused on discovering new ways to increase understanding, diagnosis and treatment of Alzheimer’s disease and other dementias. Outstanding researchers have opportunities here to gain experience working on multidisciplinary studies that involve local, national and international collaborators. Research studies range from genetics and medical neuroscience to medical and molecular genetics and computer science/bioinformatics–and beyond.